• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    $1Bn Vaccine and Antivenom Manufacturing Facility in Melbourne

    PRESS RELEASE

    CSL Delays Vax Unit Spinoff As US Immunization Rates Plummet

    FIERCE PHARMA

    CSL Appoints Ken Lim as CFO, Shares Gain

    REUTERS

    CSL Invests $117 M for VarmX Acquisition, Coagulation Treatment

    BUSINESSWIRE

    CSL Revamps Business: Vaccine Spinout, 15% Staff Cut

    BIOSPACE

    CSL To Spin Off Influenza Vaccine Unit

    REUTERS

    Valneva, CSL Seqirus Sign Exclusive Vaccine Deal for Germany

    GLOBENEWSWIRE

    In competitive HAE market, CSL gains FDA approval for Andembry

    FIERCE PHARMA

    Europe Approves CSL and Arcturus Therapeutics’ Kostaive

    BUSINESSWIRE

    GSK, Sanofi, CSL nab BARDA funding for bird flu shots

    FIERCE PHARMA

    CSL Seqirus Announces Fifth BARDA Award For Avian Flu

    PR NEWSWIRE

    CSL gets $121 mln to increase stockpile for bird flu vaccines

    REUTERS

    US nears deal to fund Moderna`s bird flu vaccine trial, FT reports

    REUTERS

    US, European nations consider vaccinating workers exposed to bird flu

    REUTERS

    US FDA approves Pfizer`s gene therapy for rare bleeding disorder

    REUTERS

    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

    BUSINESSWIRE

    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

    BUSINESSWIRE

    CSL`s Garadacimab Receives FDA and EMA Filing Acceptance

    PR NEWSWIRE

    CSL Seqirus Announces Third U.S. Gov. Award in Relation to Influenza A(H5N8)

    PR NEWSWIRE

    CSL Begins Shipping Portfolio of Influenza Vaccines for the 2023/24 U.S. Season

    PR NEWSWIRE

    CSL Opens New, State-of-the-Art Vaccine R&D Facility in Waltham, Massachusetts

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.